Avadel Pharmaceuticals Plc ADR (AVDL)

$10.84 +0.19 (1.78%)
Market Cap 1.00B
Revenue (ttm) 169.12M
Net Income (ttm) -48.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 58.15
Profit Margin -28.87%
Debt to Equity Ratio 0.00
Volume 1,561,449
Avg Vol 1,470,102
Day's Range N/A - N/A
Shares Out 96.74M
Stochastic %K 99%
Beta 1.42
Analysts Strong Sell
Price Target $16.43

Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 a...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 353 1 901 5201
Address:
10 Earlsfort Terrace, Dublin, Ireland
Tiffanytrump
Tiffanytrump Jul. 17 at 6:08 PM
$AVDL ftw. It’s one of a kind. Who wants to wake up in the middle of the night. Micdrop😢
1 · Reply
LarryYMB
LarryYMB Jul. 17 at 3:38 PM
$AVDL vote them out! All!
0 · Reply
Otus
Otus Jul. 17 at 3:31 PM
$AVDL The fight for 11 plus is on!
0 · Reply
Everest17
Everest17 Jul. 16 at 4:30 PM
$AVDL Classic, piece of shit. Can’t hold a percent gain
1 · Reply
LarryYMB
LarryYMB Jul. 16 at 1:44 PM
$AVDL is funny how nicely the stock behave when the fake selling stops , thank you AI overlords!
0 · Reply
Breakfast_Stouts
Breakfast_Stouts Jul. 15 at 5:51 PM
$AVDL decent volume on the 10 calls for July and August. Hmmm.
1 · Reply
pooppants
pooppants Jul. 15 at 2:05 PM
$AVDL Hi all, new here for a couple weeks. What seems to be the holdback on this stock? From what I’ve researched, it only has one competitor, and has demonstrated superiority to this competitor. On top of that, patients don’t have to wake up in the middle of the night to take a second pill. Is there anything I’m missing?
1 · Reply
speed717
speed717 Jul. 15 at 10:52 AM
$AVDL A lot of questions have surrounded the potential for Orexins to dethrone Oxybates as a treatment for Narcolepsy. Yesterday Takeda had phase 3 results for their Orexin product and claimed strong results. The number 1 adverse event was INSOMNIA!!! Not exactly what I want if I have a sleep disorder. At best Orexins will be used in conjunction with Oxybates as an awakening treatment, but Narcolepsy is a sleep disorder that requires patients to get the correct sleep cycles every night to avoid the daytime sleepiness. I don’t feel threatened.
0 · Reply
Rabinovich
Rabinovich Jul. 14 at 7:39 PM
$AVDL 'Our findings are deeply troubling'. '.... suggests something far more serious: a systemic failure – or worse, deliberate manipulation'. Fascinating letter.
0 · Reply
Fred_G_Sanford
Fred_G_Sanford Jul. 14 at 1:36 PM
$AVDL ASL claiming voting fraud a la Trump at the annual meeting FIVE years ago is preposterous poppycock!
2 · Reply
Latest News on AVDL
ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders

Jul 14, 2025, 7:00 AM EDT - 3 days ago

ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders

ASL pushes for board shakeup at Avadel over handling of sleep drug rollout

Jun 30, 2025, 9:41 AM EDT - 17 days ago

ASL pushes for board shakeup at Avadel over handling of sleep drug rollout

Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation

Jun 30, 2025, 7:00 AM EDT - 17 days ago

Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation

ASL Strategic Value Fund targets Avadel board over Lumryz drug mismanagement, WSJ reports

Jun 29, 2025, 10:30 PM EDT - 17 days ago

ASL Strategic Value Fund targets Avadel board over Lumryz drug mismanagement, WSJ reports

An investor in the narcolepsy drugmaker Avadel Pharmaceuticals plans to call for shareholders to vote out the company's entire board of directors, ratcheting up pressure

Jun 29, 2025, 9:00 PM EDT - 17 days ago

An investor in the narcolepsy drugmaker Avadel Pharmaceuticals plans to call for shareholders to vote out the company's entire board of directors, ratcheting up pressure

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Jun 16, 2025, 4:05 PM EDT - 4 weeks ago

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Jun 5, 2025, 7:30 AM EDT - 6 weeks ago

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025

May 29, 2025, 4:05 PM EDT - 7 weeks ago

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025

Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 7 weeks ago

Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year'

May 15, 2025, 11:43 AM EDT - 2 months ago

Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year'

Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer

May 13, 2025, 4:15 PM EDT - 2 months ago

Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer

Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 13, 2025, 8:00 AM EDT - 2 months ago

Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Avadel Pharmaceuticals plc (AVDL) Q1 2025 Earnings Call Transcript

May 7, 2025, 12:45 PM EDT - 2 months ago

Avadel Pharmaceuticals plc (AVDL) Q1 2025 Earnings Call Transcript

Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

May 7, 2025, 7:00 AM EDT - 2 months ago

Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction

May 6, 2025, 12:30 PM EDT - 2 months ago

Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7

Apr 30, 2025, 8:00 AM EDT - 2 months ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7

Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience

Apr 17, 2025, 8:00 AM EDT - 3 months ago

Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience

Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference

Apr 8, 2025, 1:30 PM EDT - 3 months ago

Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference

Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 3 months ago

Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference

Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians

Mar 25, 2025, 8:00 AM EDT - 4 months ago

Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Mar 5, 2025, 8:00 AM EST - 4 months ago

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Avadel Pharmaceuticals plc (AVDL) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 11:53 PM EST - 4 months ago

Avadel Pharmaceuticals plc (AVDL) Q4 2024 Earnings Call Transcript

Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 7:00 AM EST - 4 months ago

Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3

Feb 24, 2025, 4:05 PM EST - 5 months ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3

Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales

Feb 24, 2025, 8:00 AM EST - 5 months ago

Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales

Avadel Pharmaceuticals: Moving To A Speculative Buy

Feb 11, 2025, 6:08 PM EST - 5 months ago

Avadel Pharmaceuticals: Moving To A Speculative Buy

ASL Strategic Value Fund Letter to Avadel Pharmaceuticals (AVDL: NASDAQ) Board of Directors

Feb 10, 2025, 9:00 AM EST - 5 months ago

ASL Strategic Value Fund Letter to Avadel Pharmaceuticals (AVDL: NASDAQ) Board of Directors

3 Oversold Biotech Names

Jan 13, 2025, 12:56 PM EST - 6 months ago

3 Oversold Biotech Names

FOLD JAZZ VKTX XBI

Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook

Jan 12, 2025, 3:26 AM EST - 6 months ago

Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook

Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch

Jan 8, 2025, 4:15 PM EST - 6 months ago

Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch

Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8

Jan 3, 2025, 8:00 AM EST - 6 months ago

Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8

Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Nov 13, 2024, 8:00 AM EST - 8 months ago

Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Avadel Pharmaceuticals plc (AVDL) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 3:19 PM EST - 8 months ago

Avadel Pharmaceuticals plc (AVDL) Q3 2024 Earnings Call Transcript

Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation

Oct 31, 2024, 7:00 AM EDT - 9 months ago

Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation

US FDA expands approval for Avadel's sleep disorder drug

Oct 17, 2024, 10:03 AM EDT - 9 months ago

US FDA expands approval for Avadel's sleep disorder drug

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

Oct 17, 2024, 9:41 AM EDT - 9 months ago

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On

Sep 3, 2024, 8:30 AM EDT - 11 months ago

Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On

Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)

Sep 3, 2024, 8:00 AM EDT - 11 months ago

Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)

Avadel Pharmaceuticals plc (AVDL) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 12:27 PM EDT - 1 year ago

Avadel Pharmaceuticals plc (AVDL) Q2 2024 Earnings Call Transcript

Avadel Pharmaceuticals to Join Russell 3000® Index

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Avadel Pharmaceuticals to Join Russell 3000® Index

Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024

May 22, 2024, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024

Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

May 21, 2024, 7:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 8, 2024, 7:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8

May 1, 2024, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Apr 2, 2024, 3:40 AM EDT - 1 year ago

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

Avadel Pharmaceuticals Issues Statement On Patent Litigation

Mar 4, 2024, 3:37 PM EST - 1 year ago

Avadel Pharmaceuticals Issues Statement On Patent Litigation

Avadel Pharmaceuticals plc (AVDL) Q4 2023 Earnings Call Transcript

Mar 4, 2024, 10:43 AM EST - 1 year ago

Avadel Pharmaceuticals plc (AVDL) Q4 2023 Earnings Call Transcript

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 4, 2024, 6:30 AM EST - 1 year ago

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop

Jan 28, 2024, 2:56 AM EST - 1 year ago

Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop

Tiffanytrump
Tiffanytrump Jul. 17 at 6:08 PM
$AVDL ftw. It’s one of a kind. Who wants to wake up in the middle of the night. Micdrop😢
1 · Reply
LarryYMB
LarryYMB Jul. 17 at 3:38 PM
$AVDL vote them out! All!
0 · Reply
Otus
Otus Jul. 17 at 3:31 PM
$AVDL The fight for 11 plus is on!
0 · Reply
Everest17
Everest17 Jul. 16 at 4:30 PM
$AVDL Classic, piece of shit. Can’t hold a percent gain
1 · Reply
LarryYMB
LarryYMB Jul. 16 at 1:44 PM
$AVDL is funny how nicely the stock behave when the fake selling stops , thank you AI overlords!
0 · Reply
Breakfast_Stouts
Breakfast_Stouts Jul. 15 at 5:51 PM
$AVDL decent volume on the 10 calls for July and August. Hmmm.
1 · Reply
pooppants
pooppants Jul. 15 at 2:05 PM
$AVDL Hi all, new here for a couple weeks. What seems to be the holdback on this stock? From what I’ve researched, it only has one competitor, and has demonstrated superiority to this competitor. On top of that, patients don’t have to wake up in the middle of the night to take a second pill. Is there anything I’m missing?
1 · Reply
speed717
speed717 Jul. 15 at 10:52 AM
$AVDL A lot of questions have surrounded the potential for Orexins to dethrone Oxybates as a treatment for Narcolepsy. Yesterday Takeda had phase 3 results for their Orexin product and claimed strong results. The number 1 adverse event was INSOMNIA!!! Not exactly what I want if I have a sleep disorder. At best Orexins will be used in conjunction with Oxybates as an awakening treatment, but Narcolepsy is a sleep disorder that requires patients to get the correct sleep cycles every night to avoid the daytime sleepiness. I don’t feel threatened.
0 · Reply
Rabinovich
Rabinovich Jul. 14 at 7:39 PM
$AVDL 'Our findings are deeply troubling'. '.... suggests something far more serious: a systemic failure – or worse, deliberate manipulation'. Fascinating letter.
0 · Reply
Fred_G_Sanford
Fred_G_Sanford Jul. 14 at 1:36 PM
$AVDL ASL claiming voting fraud a la Trump at the annual meeting FIVE years ago is preposterous poppycock!
2 · Reply
speed717
speed717 Jul. 14 at 11:43 AM
$AVDL https://finance.yahoo.com/news/asl-strategic-value-fund-issues-110000236.html
1 · Reply
speed717
speed717 Jul. 14 at 11:37 AM
$AVDL
0 · Reply
speed717
speed717 Jul. 13 at 11:29 AM
$AVDL A reminder that President Trump is threatening 200% tariffs on drugs produced outside the US. Lumryz is produced in the good old USA and Xywav is not.
1 · Reply
speed717
speed717 Jul. 11 at 2:45 PM
$AVDL Remember to vote AGAINST board members. Take the time to do it, it is in everyone’s best interest.
0 · Reply
Alex_Abou_Ezzi
Alex_Abou_Ezzi Jul. 11 at 3:01 AM
$AVDL down 5% after market?!?
1 · Reply
LarryYMB
LarryYMB Jul. 10 at 7:25 PM
$AVDL something is off, another green day?
0 · Reply
Capitulation_0
Capitulation_0 Jul. 10 at 1:10 PM
$AVDL Taking market share away from xywav. Lawsuit overhang is pretty much removed. xywav did 1.4B, 30% on IH label. 225m is estimated for 2025 for LUMRYZ. Lumryz is slowly but surely taking market share. Xywav Q4 2024: ~14,150 active Xywav patients, with ~525 net adds in the quarter Q1 2025: Patient base grew to ~14,600, adding ~450 net patients, including 325 IH patients, resulting in 4,225 IH and 10,375 narcolepsy patients Q4 2024 → Q1 2025: +525 + 450 = ~975 patients added. Run-rate suggests adding ~450–525 patients each quarter → projected ~16,400–17,150 patients by year-end. LUMRYZ Q4 2024: Base of 2,500 patients on therapy Q1 2025: Grew to 2,800 patients, meaning +300 net adds in the quarter—a 50% increase from Q4 . Guidance from Avadel expects 3,400–3,600 patients by end of 2025, implying another 600–800 net adds across Jazz should be concerned about IH indication in 2026 competition. Discontinuation is similar although there's some debate around it.
0 · Reply
BlandInvestor
BlandInvestor Jul. 9 at 5:02 PM
$AVDL Whatever you say, this stock is one of the most manipulated I own:
1 · Reply
B1000
B1000 Jul. 9 at 2:29 PM
$AVDL It never holds! It’ll be back under 9 in no time
1 · Reply
Otus
Otus Jul. 9 at 2:22 PM
$AVDL first decent movement in a month. The real question is will it hold and can it be built upon.
1 · Reply
speed717
speed717 Jul. 9 at 12:01 PM
$AVDL Strange that not one analyst commented, or changed numbers after recent Appeals Court victory in Jazz vs FDA. We now have a clear path to IH approval and ODE for that indication. Once nightly dosing is even more important for IH indication. Another billion plus opportunity and no one gives a crap. Unbelievable.
1 · Reply
Capitulation_0
Capitulation_0 Jul. 8 at 5:53 PM
$AVDL New indication filing is the only overhang here. Rulings so far have cleared a way for Lumryz sales to proceed. They can continue with clinical studies...I'd also expect new indications to be approved... JAZZ should buy AVDL or move on.
1 · Reply